Strides Pharma Science Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024.

For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 22 May 2025.

Powered by Capital Market - Live News

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.

Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.

The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore).

Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products

The company?s consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24.

The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.

Powered by Capital Market - Live News